GlassScriptPhysician profile
Angelo B Sutera
NPI 1295722874
$6,041.12
in general payments reported to CMS, 2019-2025
23 companies · $2,889 in 2025
The $2,889 reported for 2025 was more than what 93% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $25.69 · 2021: $290 · 2022: $738 · 2023: $562 · 2024: $1,030 · 2025: $2,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754 · Travel and Lodging: $1,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.65 |
| Travel and Lodging | $1,727.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,951.97 | 2019-2025 | Grafix Pl, Stravix, Stravix Mesh |
| Treace Medical Concepts, INC. | $1,800.22 | 2025 | |
| Paratek Pharmaceuticals, INC. | $475.11 | 2021-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $334.81 | 2019 | |
| Organogenesis INC. | $213.83 | 2021-2023 | Puraply |
| Kerecis Limited | $173.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Stryker Corporation | $137.77 | 2019-2024 | Prostep |
| Stability Biologics, LLC | $135.00 | 2025 | |
| Averitas Pharma INC. | $132.10 | 2023-2025 | Qutenza |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2024 | Exparel |
| Integra Lifesciences Corporation | $94.45 | 2019-2022 | |
| Eclipse Technology Solutions INC. | $90.97 | 2023-2025 | |
| Grt US Holding, INC. | $65.67 | 2021-2022 | |
| Musculoskeletal Transplant Foundation INC. | $53.23 | 2021-2024 | |
| Convatec INC. | $43.60 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $33.38 | 2023 | |
| Nevro Corp. | $31.88 | 2022 | |
| Paragon 28, INC. | $31.25 | 2019-2023 | Gorilla |
| Merck Sharp & Dohme LLC | $27.14 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.10 | 2019 | |
| Solventum Corporation | $25.13 | 2025 | Activ.A.C. |
| Medtronic, INC. | $20.29 | 2022 | |
| Nabriva Therapeutics, Plc | $18.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Sutera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.